Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression

Journal of Head Trauma Rehabilitation

Volumn 29, Issue 5, 2014, Pages 391-399

  Hammond, Flora M ^a   Bickett, Allison K ^a   Norton, James H ^a   Pershad, Rashmi ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Aggression; Agitation; Amantadine; Brain injuries; Dopamine; Irritability

Indexed keywords

AMANTADINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IRRITABILITY; MALE; MENTAL DISEASE ASSESSMENT; NEUROPSYCHIATRIC INVENTORY AGGRESSION; NEUROPSYCHIATRIC INVENTORY DISTRESS; NEUROPSYCHIATRIC INVENTORY IRRITABILITY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TRAUMATIC BRAIN INJURY; BRAIN INJURY; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; AGGRESSION; AMANTADINE; BRAIN INJURIES; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES;

EID: 84920881880     PISSN: 08859701     EISSN: 1550509X     Source Type: Journal    
DOI: 10.1097/01.HTR.0000438116.56228.de     Document Type: Article

References (50)

1. Hammond FM, Davis CS, Whiteside YO, Philbrick P, Hirsch MA. Marital adjustment and stability following traumatic brain injury: a pilot qualitative analysis of spouse perspectives. J Head Trauma Rehabil. 2011;26(1):69-78.
2. Kilmer RP, Demakis GJ, Hammond FM, et al. Use of the Neuropsychiatric Inventory in traumatic brain injury: a pilot investigation. Rehabil Psychol. 2006;51:232-238.
3. Ciurli P, Formisano R, Bivona U, et al. Neuropsychiatric disorders in persons with severe traumatic brain injury: prevalence, phenomenology, and relationship with demographic, clinical, and functional features. J Head Trauma Rehabil. 2011;26(2):116-126.
4. Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165:429-442.
5. Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2003: CD003299. doi: 10.1002/14651858. CD003299.
6. Warden DL, Gordon B, McAllister TW, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006;23(10):1468-1501.
7. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury [Review]. Clin Neuropharmacol. 1989;12: (4) 258-270.
8. Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil. 2005;20(5):450-463.
9. Chandler MC, Barnhill JL, Gualtieri CT. Amantadine for the agitated head-injury patient. Brain Inj. 1988;2: (4) 309-311.
10. Gualtieri CT. Neuropsychiatry and Behavioral Pharmacology. New York: Springer-Verlag; 1991.
11. Nichels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury and rehabilitation. Brain Inj. 1994;8(8):709-718.
12. Schneider WN, Drew-Cates J, Wong TM, et al. Cognitive and behavioral efficacy of amantadine in acute trauma brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13(11):863-872.
13. Van Reekum R, Bayley M, Garner S, et al. Nof 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49-53.
14. Levin H, Kraus MF. The frontal lobes and traumatic brain injury. J Neuropsychiatry Clin Neurosci. 1994;6:443-454.
15. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery aftermotor cortex surgery. Science. 1982;217:855-857.
16. Kasamatusu T, Pettigrew JK, Ary M. Cortical recovery from effects of monocular deprivation: acceleration with norepinephrine and suppression with 6-hydroxydopamine. J Neurophysiol. 1981;45:139-162.
17. Kasamatusu T, Pettigrew JD. Preservation of binocularity after monocular deprivation in the striate cortex of kittens treated with 6-hydroxydopamine. J Comp Neurol. 1979;185:139-162.
18. Feeney DM, Weisend MP, Kline AE. Noradrenergic pharmacotherapy, intracerebral infusion and adrenal transplantation promote functional recovery after cortical damage. JNeural Transplant Plast. 1993;4(3):199-213.
19. Gualtieri CT, Evans RW. Stimulant treatment for the neurobehavioral sequelae of traumatic brain injury. Brain Inj. 1988;2(4):273-290.
20. Andersson S, Berslad J, Finset A, Grimsmo J. Amantadine in cognitive failure in patients with traumatic brain injury. Tidsskrift den Norske Laegeforening. 1992;112:2070-2072.
21. Zafonte RD, Watanabe T, Mann N. Amantadine: a potential treatment for the minimally conscious state. Brain Inj. 1998;12(7):617-621.
22. Aokl F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:35-51.
23. Peeters M, Maloteaux JM, Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett. 2003;343:205-209.
24. Gianutsos G, Stewart C, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985;110:357-361.
25. Kraus M, Smith G, Butters M, et al. Effects of the dopaminergic agents and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography. Brain Inj. 2005;19:471-479.
26. Werling LL, Keller A, Frank J, Nuwayhid S. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207:248-257.
27. Moresco R, Volonte M, Meesa C, et al. New perspectives on neurochemical effects of amantadine in the brain of Parkinson's patients: a PET raclopride study. J Neural Transmission. 2002;109:1265-1274.
28. Sawyer E, Mauro L, Ohlinger M. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother. 2008;42:247-251.
29. Allen R. Role of amantadine in the management of neurolepticinduced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol. 1983;6(suppl 1):S64-S73.
30. Evans S, Levin F, Brooks D, Garawi F. A pilot double blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31:775-782.
31. Parsons C, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723.
32. Glennon R, Young R. MDMA stimulus generalization to the 5HT1a serotonin agonist 8-hydroxyl (di-n-propylamino) tetralin. Pharmacol Biochem Behav. 2000;66:483-488.
33. Rogoz Z, Skuza G, Legutko B. Repeated cotreatment with imipramine and amantadine induces hippocampal brain derived neurotrophic factor gene expression in rats. J Physiol Pharmacol. 2007;58:219-234.
34. Caumont A, Octave J, Hermans E. Amantadine and memantine induce the expression of the glial cell line derived neurotrophic factor in C6 glioma cells. Neurosci Lett. 2006;394:196-201.
35. Hammond F, Bickett-Knotts A, Hirsch M, et al. Posttraumatic irritability and related factors. J Head Trauma Rehabil. 2006;21(5):412-413.
36. Cummings JL, Mega MS, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.
37. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210-215.
38. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
39. Derogatis LR. BSI 18. Brief Symptom Inventory 18. Minneapolis, MN: NCS Pearson; 2000.
40. Wyman PA, Cowen EL, Work WC, et al. Developmental and caregiving factors differentiating parents of young stress-affected and stress-resilient urban children: a replication and extension. Child Dev. 1999;70:645-659.
41. Berwick DM, Murphy JM, Goldman PA, et al. Performance of a 5-item mental health screening test. Med Care. 1991;29(2):87-178.
42. La Chapelle DL, Frasquillo F. An evaluation of subjective and objectivemeasures of fatigue in patients with brain injury and healthy controls. Brain Inj. 1998;12(8):649-659.
43. Fisk JD, Ritvo PF, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale. Clin Infect Dis 1994;18(suppl 1):S79-S83.
44. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9(2):222-230.
45. Leone H, Polsonetti BW. Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? J Clin Pharm Ther. 2005;30:101-104.
46. Tenovuo O. Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury. Cur Opin Neurol. 2006;19:528-533.
47. Zasler N. Advances in neuropharmacological rehabilitation for brain dysfunction. Brain Inj. 1992;6:1-14.
48. Bradley PB. Introduction to Neuropharmacology. London: Wright Publishing Company; 1989.
49. Wechsler ME, Kelle JM, Boyd IOE, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. NEJM. 2011;365:119-126.
50. Putting the placebo effect to work. Harvard Letter. http://www.health.harvard.edu/newsletters/Harvard-Health-Letter/2012/April/putting-the-placebo-effect-to-work. Published 2012. Accessed October 23, 2013.